EMA validates application for Tepotinib for treatment of advanced NSCLC with METex14 skipping alterations

This article was originally published here

With this validation, the application is complete, and the EMA will now begin the review procedure. Tepotinib is a highly selective oral MET inhibitor that is administered once

The post EMA validates application for Tepotinib for treatment of advanced NSCLC with METex14 skipping alterations appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply